Insight Molecular Diagnostics Inc. (IMDX) key performance indicators and operating metrics (25 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Medicare reimbursement rate for GraftAssureCore | 2.75K | FY2026-Q1 |
| U.S. transplant centers expressing interest in GALACTIC registry | 34.00 | FY2026-Q1 |
| GraftAssure deployment sites | 22.00 | FY2026-Q2 |
| Adjusted loss before interest, taxes, depreciation and amortization | -7.8M | FY2026-Q2 |
| Adjusted net loss | -8.3M | FY2026-Q2 |
| Non-generally accepted accounting principles loss from operations | -6.6M | FY2025-Q3 |
| GraftAssure deployment continents | 3.00 | FY2026-Q2 |
| GraftAssure deployment countries | 9.00 | FY2026-Q2 |
| General and administrative expenses | 2.9M | FY2026-Q2 |
| Research and development expenses | 2.02M | FY2026-Q2 |
| Sales and marketing expenses | 707K | FY2026-Q2 |
| Gross margin | 65.70 percent | FY2026-Q2 |
| Laboratory Services revenue | 218K | FY2026-Q2 |
| US revenue | 218K | FY2026-Q2 |
Back to IMDX overview · IMDX earnings · IMDX holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.